GlassScriptPhysician profile
Paul E Walsky
NPI 1902902620
$1,341.92
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $335 · 2021: $267 · 2022: $411 · 2023: $30.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $30.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $30.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $244.76 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $171.85 | 2019-2022 | |
| Biogen, INC. | $150.71 | 2019-2022 | |
| Amgen INC. | $138.10 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $105.99 | 2022-2023 | Austedo |
| Lilly USA, LLC | $81.81 | 2020-2021 | |
| Emd Serono, INC. | $74.66 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $70.35 | 2022 | |
| Sk Life Science, INC. | $66.18 | 2021 | |
| Genzyme Corporation | $59.21 | 2022 | |
| Lundbeck LLC | $37.19 | 2020 | |
| Jazz Pharmaceuticals INC. | $33.36 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $24.89 | 2020 | |
| Abbott Laboratories | $22.08 | 2022 | |
| Ge Healthcare | $20.68 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $16.14 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Grifols USA, LLC | $12.42 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Walsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.